Burns - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 88 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Burns - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Burns - Pipeline Review, H2 2014', provides an overview of the Burns's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Burns
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Burns and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Burns products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Burns pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Burns
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Burns Overview 9
Therapeutics Development 10
Pipeline Products for Burns - Overview 10
Pipeline Products for Burns - Comparative Analysis 11
Burns - Therapeutics under Development by Companies 12
Burns - Therapeutics under Investigation by Universities/Institutes 14
Burns - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Burns - Products under Development by Companies 19
Burns - Products under Investigation by Universities/Institutes 20
Burns - Companies Involved in Therapeutics Development 21
Adocia 21
AlgiPharma AS 22
Biogenomics Limited 23
Birken AG 24
CytoTools AG 25
Fibrocell Science, Inc. 26
HanAll Biopharma Co., Ltd. 27
Kasiak Research Pvt. Ltd. 28
Kuros Biosurgery AG 29
MediWound Ltd. 30
Novan, Inc. 31
Novartis AG 32
Se-cure Pharmaceuticals Ltd. 33
Stemnion, Inc 34
Stratatech Corporation 35
USV Limited 36
vida therapeutics inc. 37
Xiber Science GmbH 38
Burns - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
albumin (human) (recombinant) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Amnion Derived Cellular Cytokine Solution - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
azficel-T - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
bromelains - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BVS-857 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
coagulation factor XIVa (human) - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Drug for Dermatology and Infectious Diseases - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
epidermal growth factor biosimilar - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
G-10 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HL-156Fib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
IMSP-001 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
KUR-212 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Monoclonal Antibody for Inflammation, Burns and Wounds - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
OleogelS-10 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Oligomer G for Wounds And Burns - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PEP-04 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Refaheal - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
SC-106 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecule for Chronic Wounds and Burns - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
StrataGraft Skin Tissue - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
V-2248 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Xib-1302 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Burns - Recent Pipeline Updates 78
Burns - Dormant Projects 82
Burns - Discontinued Products 83
Burns - Product Development Milestones 84
Featured News & Press Releases 84
Jul 16, 2014: MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health 84
Aug 12, 2009: Kuros Announces Encouraging Phase IIa Data With KUR-212 In Patients With Burns Requiring Mesh Grafting 85
Aug 11, 2008: Kuros Announces Results Of One-Month Follow-Up Of Phase IIa Trial Of KUR-212 In Patients With Burns Requiring Mesh Grafting 85
Feb 04, 2008: Kuros Completes Patient Recruitment In Phase Lia Trial Of KUR 212 In Patients With Severe Burns Requiring Meshed Skin Grafting 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88

List of Tables
Number of Products under Development for Burns, H2 2014 10
Number of Products under Development for Burns - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Burns - Pipeline by Adocia, H2 2014 21
Burns - Pipeline by AlgiPharma AS, H2 2014 22
Burns - Pipeline by Biogenomics Limited, H2 2014 23
Burns - Pipeline by Birken AG, H2 2014 24
Burns - Pipeline by CytoTools AG, H2 2014 25
Burns - Pipeline by Fibrocell Science, Inc., H2 2014 26
Burns - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 27
Burns - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 28
Burns - Pipeline by Kuros Biosurgery AG, H2 2014 29
Burns - Pipeline by MediWound Ltd., H2 2014 30
Burns - Pipeline by Novan, Inc., H2 2014 31
Burns - Pipeline by Novartis AG, H2 2014 32
Burns - Pipeline by Se-cure Pharmaceuticals Ltd., H2 2014 33
Burns - Pipeline by Stemnion, Inc, H2 2014 34
Burns - Pipeline by Stratatech Corporation, H2 2014 35
Burns - Pipeline by USV Limited, H2 2014 36
Burns - Pipeline by vida therapeutics inc., H2 2014 37
Burns - Pipeline by Xiber Science GmbH, H2 2014 38
Assessment by Monotherapy Products, H2 2014 39
Number of Products by Stage and Target, H2 2014 41
Number of Products by Stage and Mechanism of Action, H2 2014 43
Number of Products by Stage and Route of Administration, H2 2014 45
Number of Products by Stage and Molecule Type, H2 2014 47
Burns Therapeutics - Recent Pipeline Updates, H2 2014 78
Burns - Dormant Projects, H2 2014 82
Burns - Discontinued Products, H2 2014 83